Medicure Announces Third Quarter Financial Results

Medicure Inc. (CVE:MPH) announced its third quarter financial results for the period ending on September 30, 2015.
According to the press release:

Quarter Three HighlightsRecorded net revenue of $5.4 million during the quarter ended September 30, 2015, an increase of 155% compared to $2.1 million for the quarter ended August 31, 2014 and an increase of 133% compared to $2.3 million for the three months ended September 30, 2014; Third quarter earnings before interest, taxes, depreciation and amortization (EBITDA)1 adjusted for one-time regulatory costs and for share-based compensation was $2.1 million compared to $805,000 for the quarter ended August 31, 2014. Announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the label for AGGRASTAT (tirofiban HCl) to include the treatment of patients presenting with ST segment elevation myocardial infarction (STEMI). Total one-time costs related to the sNDA in the quarter were $1.9 million.
In December of 2014, the Company announced a change in its financial year-end from May 31 to December 31. As a result of the change in year-end, results for the current quarter ending on September 30, 2015 are compared to the closest comparable fiscal period, which is the quarter ending on August 31, 2014.

Click here to read the full press release.